Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04669171 · ClinicalTrials.gov registry record · Phase 1
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
A Phase 1 study of Follicular Lymphoma and Marginal Zone Lymphoma, sponsored by Enterome.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 12
- Study locations
NCT04669171: Recruiting Phase 1 study of Follicular Lymphoma and Marginal Zone Lymphoma, sponsored by Enterome.
NCT04669171 is a Phase 1 study of Follicular Lymphoma and Marginal Zone Lymphoma that is actively recruiting participants, run by Enterome. The registered enrollment target is 80 participants, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (40% lower). The trial reports 12 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04669171, a Phase 1 study of Follicular Lymphoma and Marginal Zone Lymphoma, is actively recruiting participants, sponsored by Enterome.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
Primary Outcome
Incidences of adverse events, Treatment-Emergent Adverse events, Serious Adverse Events, Deaths, and Laboratory Abnormalities Using the National Cancer Institute-Common Terminology Criteria for Adverse events (NCI-CTCAE) V5.0.
Conditions Studied
Interventions
- BIOLOGICAL rituximab
- DRUG lenalidomide
- BIOLOGICAL EO2463
Study Locations (12)
Other
- CHU d'Amiens-Picardie - Hopital SUD - Amiens
- University of Bologna - Bologna
- IRCCS Policlinico San Matteo Foundation - University of Pavia - Naples
- IRCCS Policlinico San Matteo Foundation - University of Pavia - Pavia
- University Hospital Vall d'Hebron, Institute of Oncology - Barcelona
- Clinica Universidad de Navarra - Madrid
- Clinica Universidad de Navarra - Pamplona
- Hospital Clinico Universitario de Salamanca - Salamanca
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester
New York
- University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) - Rochester
Washington
- University of Washington-Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-07-05 |
| Est. Completion | 2034-05-30 |
| Phase | Phase 1 |
What NCT04669171 shows while recruiting
NCT04669171 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (40% lower).
The record links to 2 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which rituximab is the first listed.
NCT04669171 lists 12 locations in 5 states (Other, Massachusetts, Minnesota).
Frequently Asked Questions
What is clinical trial NCT04669171 about?
NCT04669171 is a clinical study titled "A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma". The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
What is the current status of trial NCT04669171?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2021-07-05. Estimated completion is 2034-05-30.
What conditions does trial NCT04669171 study?
This clinical trial studies the following conditions: Follicular Lymphoma, Marginal Zone Lymphoma.
What interventions are being tested in trial NCT04669171?
The interventions under investigation include: rituximab (BIOLOGICAL), lenalidomide (DRUG), EO2463 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04669171?
This trial is sponsored by Enterome, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04669171 being conducted?
This trial has 12 study locations across Massachusetts, Minnesota, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04669171's enrollment target sits among peer trials
80 37th of 89 higher than 53 of 89 other Follicular Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI